R&D | Cutting-edge science and innovative research

News

Boehringer forges $7bn alliance with China's SBP Group

Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T cell engagers from China's Sino Biopharma.

R&D

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

News

AbbVie invests £120m in UK expansion

AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot.

News

German sites added to Europe's cardiometabolic R&D network

The BioInnovation Institute (BII) has expanded a European network to develop drugs for cardiometabolic diseases and launch new biotechs into Germany.

News

Case study backs YolTech's AATD gene therapy

A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.

Views & Analysis

Virtual trials take centre stage during COVID-19

We speak to Bruce Hellman, CEO of uMotif, the patient-centric data capture platform specialists, to find out how virtual trials are evolving and why they are more important than ever in

Views & Analysis

Coronavirus pharma news roundup – 03/04/20

After pharma ramped up its response to coronaviru

News

Some pharmas acting like “toilet roll profiteers” on COVID-1...

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Boehringer forges $7bn alliance with China's SBP Group

Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T cell engagers from China's Sino Biopharma.

News

AbbVie invests £120m in UK expansion

AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

R&D

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

R&D

Auto vacuum sealed vaccines in manufacturing plant

Reliability in life sciences logistics: What good looks like

What constitutes a reliable supply chain is changing rapidly.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.